| Literature DB >> 32612839 |
Toshikazu Abe1,2,3, Kazuma Yamakawa4, Hiroshi Ogura5, Shigeki Kushimoto6, Daizoh Saitoh7, Seitaro Fujishima8, Yasuhiro Otomo9, Joji Kotani10, Yutaka Umemura5, Yuichiro Sakamoto11, Junichi Sasaki12, Yasukazu Shiino13, Naoshi Takeyama14, Takehiko Tarui15, Shin-Ichiro Shiraishi16, Ryosuke Tsuruta17, Taka-Aki Nakada18, Toru Hifumi19, Akiyoshi Hagiwara20, Masashi Ueyama21, Norio Yamashita22, Tomohiko Masuno23, Hiroto Ikeda24, Akira Komori25, Hiroki Iriyama25, Satoshi Gando26,27.
Abstract
BACKGROUND: Diagnosing sepsis remains difficult because it is not a single disease but a syndrome with various pathogen- and host factor-associated symptoms. Sepsis-3 was established to improve risk stratification among patients with infection based on organ failures, but it has been still controversial compared with previous definitions. Therefore, we aimed to describe characteristics of patients who met sepsis-2 (severe sepsis) and sepsis-3 definitions.Entities:
Keywords: In-hospital mortality; Intensive care unit; Sepsis
Year: 2020 PMID: 32612839 PMCID: PMC7324770 DOI: 10.1186/s40560-020-00465-0
Source DB: PubMed Journal: J Intensive Care ISSN: 2052-0492
Fig. 1Taxonomy and in-hospital mortality among patients with infection admitted to the intensive care unit
Case mix characteristics for admissions to ICU with suspected infection (by sepsis-2 and sepsis-3 definitions)
| Sepsis-2 | Sepsis-3 | Sepsis-2 and sepsis-3 | Sepsis-2 and no sepsis-3 | No sepsis-2 and sepsis-3 | No sepsis-2 and no sepsis-3 | ||
|---|---|---|---|---|---|---|---|
| Variables | |||||||
| Age at admission (year) | 72 (60–81) | 72 (60–81) | 73 (61–81) | 69 (57–75) | 66 (57–81) | 70 (55–79) | |
| Gender (male) | 299 (56.4) | 318 (55.9) | 281 (56.1) | 18 (62.1) | 37 (54.4) | 13 (65.0) | |
| BMI (kg/m2) | 21.8 (19.4–24.3) | 21.9 (19.3–24.3) | 21.9 (19.5–24.3) | 21.3 (19.3–24.2) | 21.8 (18.3–24.2) | 23.4 (19.2–26.3) | |
| Admission source | Emergency department | 304 (57.4) | 317 (55.7) | 285 (56.9) | 19 (65.5) | 32 (47.1) | 14 (70.0) |
| Non–ED (hospital/dept. transfers) | 204 (38.5) | 230 (40.4) | 200 (39.9) | 4 (13.8) | 30 (44.1) | 2 (10.0) | |
| Intensive care unit | 22 (4.2) | 22 (3.9) | 16 (3.2) | 6 (20.7) | 6 (8.8) | 4 (20.0) | |
| Charlson comorbidity index | 0 | 156 (29.4) | 169 (29.7) | 147 (29.3) | 9 (31.0) | 22 (32.3) | 8 (40.0) |
| 1–2 | 227 (42.8) | 249 (43.8) | 214 (42.7) | 13 (44.8) | 35 (51.5) | 8 (40.0) | |
| 3–4 | 104 (19.6) | 105 (18.5) | 99 (19.8) | 5 (17.2) | 6 (8.8) | 2 (10.0) | |
| > 4 | 43 (8.1) | 46 (8.1) | 41 (8.2) | 2 (6.9) | 5 (7.4) | 2 (10.0) | |
| Clinical Frailty Scale | Fit (CFS 1–3) | 269 (50.9) | 289 (50.8) | 249 (49.8) | 20 (71.4) | 40 (58.8) | 12 (60.0) |
| Pre–frail (CFS 4) | 90 (17.0) | 100 (17.6) | 89 (17.8) | 1 (3.6) | 11 (16.2) | 4 (20.0) | |
| Frail (CFS 5–9) | 169 (32.0) | 179 (31.5) | 162 (32.4) | 87(25.0) | 17 (25.0) | 4 (20.0) | |
| Immuno–insufficiency at APACHE II | 110 (20.8) | 111 (19.6) | 101 (20.2) | 9 (31.0) | 10 (14.9) | 3 (15.0) | |
| Baseline SOFA for sepsis-3 | 0 (0–1) | 0 (0–1) | 0 (0–1) | 4 (0–8) | 0 (0–0) | 1 (0–3) | |
| Glasgow Coma Scale | 12 (7–14) | 12 (7–15) | 11 (7–14) | 14 (11–15) | 14 (10–15) | 15 (14–15) | |
| Intubated | 225 (42.6) | 226 (39.7) | 212 (42.3) | 13 (44.8) | 14 (20.6) | 5 (26.3) | |
| Systolic blood pressure (mmHg) | 102 (82–126) | 105 (84–128) | 101 (82–125) | 122 (107–143) | 122 (107–141) | 123 (111–143) | |
| Heat rate (/min) | 107 (90–124) | 107 (89–122) | 108 (91–124) | 93 (82–108) | 90 (80–108) | 90 (79–106) | |
| Respiratory rate (/min) | 24 (19–30) | 24 (19–30) | 24 (19–30) | 19 (17–24) | 20 (18–26) | 20 (19–25) | |
| Body temperature (°C) | 37.3 (36.5–38.5) | 37.4 (36.5–38.4) | 37.4 (36.5–38.5) | 37.1 (36.3–38.5) | 37.5 (36.8–38.3) | 37.7 (36.7–38.3) | |
| Lactate (mmol/L) | 2.9 (1.7–4.9) | 2.7 (1.5–4.7) | 3.1 (1.7–5.1) | 2.1 (1.4–2.9) | 1.2 (0.9–1.8) | 1.0 (0.9–1.6) | |
| Positive blood cultures | 252 (50.0) | 261 (48.4) | 245 (51.3) | 7 (26.9) | 16 (23.5) | 4 (23.5) | |
| Site of infection | Lung | 200 (37.7) | 208 (36.6) | 192 (38.3) | 8 (27.6) | 16 (23.5) | 8 (40.0) |
| Abdomen | 111 (20.9) | 119 (20.9) | 101 (20.2) | 10 (34.5) | 18 (26.5) | 2 (10.0) | |
| Urinary tract | 91 (17.2) | 101 (17.8) | 89 (17.8) | 2 (6.9) | 12 (17.7) | 3 (15.0) | |
| Soft tissue | 65 (12.3) | 70 (12.3) | 60 (12.0) | 5 (17.2) | 10 (14.7) | 6 (30.0) | |
| Central nervous system | 11 (2.1) | 13 (2.3) | 10 (2.0) | 1 (3.5) | 3 (4.4) | 1 (5.0) | |
| Intravenous catheter | 4 (0.8) | 4 (0.7) | 4 (0.8) | 0 | 0 | 0 | |
| Osteoarticular | 4 (0.8) | 6 (1.1) | 4 (0.8) | 0 | 2 (2.9) | 0 | |
| Endocardium | 1 (0.2) | 1 (0.2) | 1 (0.2) | 0 | 0 | 0 | |
| Wound | 5 (0.9) | 5 (0.9) | 4 (0.8) | 1 (3.5) | 1 (1.5) | 0 | |
| Implant device | 2 (0.4) | 2 (0.4) | 2 (0.4) | 0 | 0 | 0 | |
| Other | 14 (2.6) | 16 (2.8) | 13 (2.6) | 1 (3.5) | 3 (4.4) | 0 | |
| Unidentified | 22 (4.2) | 24 (4.2) | 21 (4.2) | 1 (3.5) | 3 (4.4) | 0 | |
| Organ dysfunction on arrival | Acute lung injury with pneumonia | 127 (24.0) | 124 (21.8) | 124 (24.8) | 3 (10.3) | 0 | 0 |
| Acute lung injury without pneumonia | 96 (18.2) | 99 (17.5) | 94 (18.8) | 2 (7.1) | 5 (7.4) | 0 | |
| ARDS (Berlin criteria) | 57 (10.9) | 60 (10.7) | 56 (11.3) | 1 (3.6) | 4 (6.0) | 0 | |
| Mechanical ventilation use | 227 (43.0) | 230 (40.6) | 215 (43.1) | 12 (41.4) | 15 (22.1) | 4 (22.2) | |
| Urine output (ml/24 h) | 896 (404–1488) | 910 (407–1503) | 873 (395–1440) | 1220 (787–1767) | 1147 (723–1770) | 1300 (930–1830) | |
| Oliguria | 238 (45.1) | 231 (40.8) | 226 (45.3) | 12 (41.4) | 5 (7.4) | 3 (15.0) | |
| Acute kidney injury in APACHE II | 257 (48.7) | 263 (46.4) | 251 (50.3) | 6 (20.7) | 12 (17.7) | 0 | |
| Sepsis-2 shock criteria | 297 (56.0) | 288 (50.6) | 288 (57.5) | 9 (31.0) | 0 | 0 | |
| Sepsis-3 shock criteria | 108 (20.4) | 107 (18.8) | 106 (21.2) | 2 (6.9) | 1 (1.5) | 0 | |
| SIRS ≥ 2 | 530 (100) | 549 (96.5) | 501 (100) | 29 (100) | 48 (70.6) | 14 (70.0) | |
| qSOFA ≥ 2 | 345 (65.1) | 356 (62.6) | 336 (67.1) | 9 (31.0) | 20 (29.4) | 3 (15.0) | |
| SOFA score | 8 (5–11) | 8 (5–11) | 8 (6–11) | 5 (1–8) | 4 (3–5) | 1 (1–2) | |
| APACHE II score | 21 (15–28) | 20 (15–27) | 21 (16–28) | 13 (10–18) | 14 (10–17) | 11 (7–14) | |
Reported counts (proportions) for categorical variables and median (interquartile range) for continuous variables
Missing; BMI = 5; Clinical Frailty Scale = 2; Immuno-insufficiency at APACHE II = 3; Intubation = 1; Systolic blood pressure = 2; Heart rate = 1; Body temperature = 1; Lactate = 14; Blood culture = 36; Acute lung injury without pneumonia = 3; ARDS = 9; Mechanical ventilation use = 4; Urine output = 36; Oliguria = 2; Acute kidney injury at APACHE II = 2
BMI body mass index, ED emergency department, ICU intensive care unit, CFS Clinical Frailty Scale, APACHE II Acute physiology and chronic health evaluation II, SOFA sequential (sepsis–related) organ failure assessment, WBC white blood cell, ARDS acute respiratory distress syndrome, SIRS systemic inflammatory response syndrome
Pathogens and antibiotics according to the sepsis definitions
| Sepsis-2 | Sepsis-3 | Sepsis-2 and sepsis-3 | Sepsis-2 and no sepsis-3 | No sepsis-2 and sepsis-3 | No sepsis-2 and no sepsis-3 | ||
|---|---|---|---|---|---|---|---|
| Variables | |||||||
| Microbiology of blood cultures | |||||||
| Gram-negative | E. coli | 84 (15.9) | 89 (15.6) | 84 (16.8) | 0 | 5 (7.4) | 0 |
| Klebsiella | 35 (6.6) | 34 (6.0) | 34 (6.8) | 1 (3.5) | 0 | 1 (5.0) | |
| Pseudomonas | 2 (0.4) | 2 (0.4) | 2 (0.4) | 0 | 0 | 0 | |
| Gram-positive | Staphylococci | 62 (11.7) | 66 (11.6) | 60 (12.0) | 2 (6.9) | 6 (8.8) | 0 |
| Streptococci | 43 (8.1) | 45 (7.9) | 42 (8.4) | 1 (3.5) | 3 (4.4) | 1 (5.0) | |
| MRSA | 5 (0.9) | 6 (1.1) | 5 (1.0) | 0 | 1 (1.5) | 0 | |
| Enterococcus | 12 (2.3) | 12 (2.1) | 12 (2.4) | 0 | 0 | 0 | |
| Anaerobic | 14 (2.6) | 12 (2.1) | 12 (2.4) | 2 (6.9) | 0 | 0 | |
| Fungi | 2 (0.4) | 2 (0.4) | 2 (0.4) | 0 | 0 | 0 | |
| Antibiotics | |||||||
| Penicillin derivative (PCG, ABPC, ABPC/MCIPC) | 21 (4.0) | 27 (4.8) | 21 (4.2) | 0 | 6 (8.8) | 1 (5.0) | |
| Ampicillin/sulbactam | 69 (13.0) | 77 (13.5) | 66 (13.2) | 3 (10.3) | 11 (16.2) | 7 (35.0) | |
| PIPC/TAZ | 73 (13.8) | 73 (12.8) | 64 (12.8) | 9 (31.0) | 9 (13.2) | 6 (30.0) | |
| First generation cephalosporin | 11 (2.1) | 11 (2.0) | 9 (1.8) | 2 (6.9) | 2 (2.9) | 3 (15.0) | |
| Second generation cephalosporin (CTM, CMZ, FMOX) | 13 (2.5) | 17 (3.0) | 11 (2.2) | 2 (6.9) | 6 (8.8) | 0 | |
| Third generation cephalosporin (CTX, CPZ, CTRX) | 60 (11.3) | 67 (11.8) | 57 (11.4) | 3 (10.3) | 10 (14.7) | 1 (5.0) | |
| Third generation cephalosporin against pseudomonas | 3 (0.6) | 3 (0.5) | 3 (0.6) | 0 | 0 | 0 | |
| Fourth generation cephalosporin against pseudomonas | 30 (5.7) | 29 (5.1) | 29 (5.8) | 1 (3.5) | 0 | 0 | |
| Carbapenem | 279 (52.6) | 291 (51.1) | 268 (53.5) | 11 (37.9) | 23 (33.8) | 3 (15.0) | |
| Aminoglycoside | 0 | 0 | 0 | 0 | 0 | 0 | |
| Quinolone | 32 (6.0) | 35 (6.2) | 32 (6.4) | 0 | 3 (4.4) | 0 | |
| Tetracycline | 3 (0.6) | 3 (0.5) | 3 (0.6) | 0 | 0 | 0 | |
| Macrolide | 29 (5.5) | 29 (5.1) | 29 (5.8) | 0 | 0 | 0 | |
| Metronidazole | 18 (3.4) | 18 (3.2) | 18 (3.6) | 0 | 0 | 0 | |
| CLDM | 23 (4.3) | 24 (4.2) | 20 (4.0) | 3 (10.3) | 4 (5.9) | 1 (5.0) | |
| Vancomycin | 81 (15.3) | 80 (14.1) | 75 (15.0) | 6 (20.7) | 5 (7.4) | 4 (20.0) | |
| Other anti–methicillin-resistant staphylococcus aureus drugs | 45 (8.5) | 48 (8.4) | 45 (9.0) | 0 | 3 (4.4) | 0 | |
| Antifungus | 28 (5.3) | 30 (5.3) | 28 (5.6) | 0 | 2 (2.9) | 1 (5.0) | |
| Others (ST, CLL, FOM, SBT/CPZ, AMPC) | 10 (1.9) | 11 (1.9) | 10 (2.0) | 0 | 1 (1.5) | 1 (5.0) | |
Reported counts (proportions)
ICU intensive care unit, PCG penicillin G, ABPC ampicillin, ABPC/MCIPC ampicillin/cloxacillin, PIPC/TAZ tazobactam/piperacillin, CTM cefotiam, CMZ cefmetazole, FMOX flomoxef, CTX cefotaxime, CPZ cefoperazone, CTRX ceftriaxone, CLDM clindamycin, ST sulfamethoxazole-trimethoprim, CLL cefaclor, FOM fosfomycin, SBT/CPZ sulbactam/cefoperazone, AMPC amoxicillin, MRSA methicillin-resistant Staphylococcus aureus
Outcomes according to the sepsis definitions
| Sepsis-2 | Sepsis-3 | Sepsis-2 and sepsis-3 | Sepsis-2 and no sepsis-3 | No sepsis-2 and sepsis-3 | No sepsis-2 and no sepsis-3 | ||
|---|---|---|---|---|---|---|---|
| Outcomes | |||||||
| In-hospital mortality | All | 114/526 (21.7) | 112/565 (19.8) | 109/497 (21.9) | 5/29 (17.2) | 3/68 (4.4) | 0/19 (0) |
| Shock Sepsis-2 Criteria | 80/295 (27.1) | 78/286 (27.3) | 78/286 (27.3) | 2/9 (22.2) | 0 | 0 | |
| Shock Sepsis-3 Criteria | 36/107 (33.6) | 36/106 (34.0) | 36/105 (34.3) | 0/2 (0) | 0/1 (0) | 0 | |
| Patients from ED | 57/303 (18.8) | 55/316 (17.4) | 54/284 (19.0) | 3/19 (15.8) | 1/32 (3.1) | 0/13 (0) | |
| Survivor dispositions | Home | 152/526 (28.9) | 171/565 (30.3) | 140/497 (28.2) | 12/29 (41.4) | 31/68 (45.6) | 10/19 (52.6) |
| Transfer | 260/526 (49.4) | 282/565 (49.9) | 248/497 (49.9) | 12/29 (41.4) | 34/68 (50.0) | 9/19 (47.4) | |
| 28-day mortality | 98/503 (19.5) | 99/536 (18.5) | 96/474 (20.3) | 2/29 (6.9) | 3/62 (4.8) | 0/19 (0) | |
| ICU-free days | 13 (0–21) | 15 (0–21) | 13 (0–21) | 19 (2–24) | 22 (15–25) | 24 (23–26) | |
| Ventilator-free days | 20 (0–28) | 21 (0–28) | 20 (0–26) | 21 (0–28) | 27 (22–28) | 28 (28–28) | |
| Length of hospital stay | 25 (11–46) | 24 (12–45) | 25 (11–46) | 31 (12–47) | 20 (12–41) | 11 (5–25) | |
Reported counts (proportions) for categorical and median (interquartile range) for continuous variables
Missing: In-hospital mortality = 5; 28-day mortality = 34; ICU-free days = 34; Ventilator-free days = 34; Length of hospital stay = 5
ICU intensive care unit, ED emergency department